Non-alcoholic fatty liver disease is characterised by a reduced polyunsaturated fatty acid transport via free fatty acids and high-density lipoproteins (HDL)

被引:21
|
作者
Mocciaro, Gabriele [1 ,2 ]
Allison, Michael [3 ]
Jenkins, Benjamin [4 ]
Azzu, Vian [3 ,4 ]
Huang-Doran, Isabel [3 ]
Herrera-Marcos, Luis Vicente [5 ]
Hall, Zoe [6 ]
Murgia, Antonio [1 ,4 ]
Susan, Davies [3 ,4 ]
Frontini, Mattia [7 ]
Vidal-Puig, Antonio
Koulman, Albert [4 ]
Griff, Julian L. [1 ,8 ]
Vacca, Michele [1 ,2 ,4 ,9 ,10 ]
机构
[1] Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England
[2] Fdn Liver Res, Roger Williams Inst Hepatol, London SE5 9NT, England
[3] Addenbrookes Hosp, Cambridge Biomed Res Ctr, Dept Med, Cambridge, England
[4] Wellcome Trust MRC Inst Metab Sci, Metab Res Labs, Cambridge CB2 0QQ, England
[5] Univ Zaragoza, Vet Fac, Dept Biochem & Mol & Cellular Biol, Zaragoza 50013, Spain
[6] Imperial Coll London, Dept Metab Digest & Reprod, Div Syst Med, Biomol Med, London SW7 2AZ, England
[7] Univ Exeter, Fac Hlth & Life Sci, Clin & Biomed Sci, Med Sch, RILD Bldg,Barrack Rd, Exeter EX2 5DW, England
[8] Univ Aberdeen, Rowett Inst, Foresterhill Campus, Aberdeen AB25 2ZD, Scotland
[9] Aldo Moro Univ Bari, Dept Interdisciplinary Med, Clin Med C Frugoni, I-70124 Bari, Italy
[10] Aldo Moro Univ Bari, Dept Interdisciplinary Med, Clin Med C Frugoni, I-70124 Bari, Italy
来源
MOLECULAR METABOLISM | 2023年 / 73卷
基金
英国医学研究理事会;
关键词
Non-alcoholic fatty liver disease (NAFLD); Obesity; Lipoprotein metabolism; Lipidomics; LC-MS; INSULIN-RESISTANCE; ADIPOSE-TISSUE; CHOLESTEROL EFFLUX; HEPATIC STEATOSIS; SCORING SYSTEM; METABOLISM; MARKERS; PHOSPHATIDYLCHOLINE; TRIACYLGLYCEROL; SPHINGOMYELIN;
D O I
10.1016/j.molmet.2023.101728
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives: Non-alcoholic fatty liver disease (NAFLD) develops due to impaired hepatic lipid fluxes and is a risk factor for chronic liver disease and atherosclerosis. Lipidomic studies consistently reported characteristic hepatic/VLDL "lipid signatures" in NAFLD; whole plasma traits are more debated. Surprisingly, the HDL lipid composition by mass spectrometry has not been characterised across the NAFLD spectrum, despite HDL being a possible source of hepatic lipids delivered from peripheral tissues alongside free fatty acids (FFA). This study characterises the HDL lipidomic signature in NAFLD, and its correlation with metabolic and liver disease markers.Methods: We used liquid chromatography-mass spectrometry to determine the whole serum and HDL lipidomic profile in 89 biopsy-proven NAFLD patients and 20 sex and age-matched controls. Results: In the whole serum of NAFLD versus controls, we report a depletion in polyunsaturated (PUFA) phospholipids (PL) and FFA; with PUFA PL being also lower in HDL, and negatively correlated with BMI, insulin resistance, triglycerides, and hepatocyte ballooning. In the HDL of the NAFLD group we also describe higher saturated ceramides, which positively correlate with insulin resistance and transaminases.Conclusion: NAFLD features lower serum lipid species containing polyunsaturated fatty acids; the most affected lipid fractions are FFA and (HDL) phospholipids; our data suggest a possible defect in the transfer of PUFA from peripheral tissues to the liver in NAFLD. Mechanistic studies are required to explore the biological implications of our findings addressing if HDL composition can influence liver metabolism and damage, thus contributing to NAFLD pathophysiology.(c) 2023 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Non-alcoholic fatty liver disease features a reduced reverse polyunsaturated fatty acid transport (free fatty acids/high-density lipoprotein) from the periphery to the liver
    Mocciaro, Gabriele
    Allison, Michael
    Jenkins, Benjamin
    Azzu, Vian
    Huang-Doran, Isabel
    Kay, Richard
    Murgia, Antonio
    Susan, Davies
    Frontini, Mattia
    Vidal-Puig, Antonio
    Koulman, Albert
    Griffin, Julian L.
    Vacca, Michele
    JOURNAL OF HEPATOLOGY, 2022, 77 : S695 - S695
  • [2] High-density lipoproteins and non-alcoholic fatty liver disease
    Hoekstra, Menno
    Van Eck, Miranda
    ATHEROSCLEROSIS PLUS, 2023, 53 : 33 - 41
  • [3] POLYUNSATURATED FATTY ACIDS AND 5-LIPOXYGENASE IN NON-ALCOHOLIC FATTY LIVER DISEASE
    Prins, Grietje Harmanna
    Jansen, Yvette J. M.
    Oosterhuis, Dorenda
    Dekker, Frank J.
    Olinga, Peter
    Gier, Konstanze
    HEPATOLOGY, 2019, 70 : 1311A - 1311A
  • [4] Supplementation of Monounsaturated and Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome
    Alisi, Anna
    Agostoni, Carlo
    Nobili, Valerio
    LIPIDS, 2011, 46 (05) : 389 - 390
  • [5] Targeting n-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease
    Valenzuela, Rodrigo
    Ortiz, Macarena
    Catalina Hernandez-Rodas, Maria
    Echeverria, Francisca
    Videla, Luis Alberto
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (31) : 5250 - 5272
  • [6] Influence of dietary polyunsaturated fatty acids on the functional properties of high-density lipoproteins (HDL)
    Han, CT
    Lee, YS
    Hopkins, RG
    Geigerman, CM
    Wander, RC
    FASEB JOURNAL, 2002, 16 (04): : A636 - A636
  • [7] Omega-3 polyunsaturated fatty acids: A pilot trial in non-alcoholic fatty liver disease
    Spadaro, L.
    Magliocco, O.
    Spampinato, D.
    Piro, S.
    Oliveri, C.
    Alagona, C.
    Papa, G.
    Rabuazzo, A. M.
    Purrello, F.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S264 - S264
  • [8] Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids
    de Castro, Gabriela S.
    Calder, Philip C.
    CLINICAL NUTRITION, 2018, 37 (01) : 37 - 55
  • [9] Biosynthesis and bioavailability of long-chain polyunsaturated fatty acids in non-alcoholic fatty liver disease
    Gormaz, Juan G.
    Rodrigo, Ramon
    Videla, Luis A.
    Beems, Megan
    PROGRESS IN LIPID RESEARCH, 2010, 49 (04) : 407 - 419
  • [10] Omega-3 polyunsaturated fatty acids: A specific liver drug for non-alcoholic fatty liver disease (NAFLD)
    Xin, Yong-Ning
    Xuan, Shi-Ying
    Zhang, Jian-Hua
    Zheng, Ming-Hua
    Guan, Hua-Shi
    MEDICAL HYPOTHESES, 2008, 71 (05) : 820 - 821